Centre azureen de cancerologie — Clinical Trial Site

15 Registered trials

6 Currently recruiting

Organisation

Centre azureen de cancerologie

Location

Mougins, France

Identifier

ORG-100049772

Address

1 Place Du Docteur Jean Luc Broquerie, 06250, France

Departments

Oncologie
Oncologie et radiothérapie
Oncologie Médicale et Radiothérapie
Oncologie Radiothérapie
Oncologue
ONCOLOGY
Radiothérapie
Radiotherapy
Service radiothérapie

Clinical trials at this site (15)

Search interface

TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting

2024-516339-28-00 EGFR inhibitor-induced folliculitis 4 2025-02-10
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
Atezolizumab After Chemo-radiotherapy for muscle-invasive bladder cancer Patients Not Eligible for Radical Cystectomy Recruiting

2024-512002-26-00 Muscle-invasive bladder cancer 4 2019-02-19
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
Study of the impact of DPD activity on the efficacy of capecitabine Ended

2024-517481-41-00 breast cancer 9 2024-10-02
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 High-risk biochemically-relapsed prostate adenocarcinom 5 2019-12-02
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended

2024-512165-13-00 Localised unresectable adenocarcinoma or squamous cell 4 2019-05-13
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended

2024-513207-13-00 oligometastatic hormone sensitive prostate cancer 4 2019-03-21
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc… Ended

2024-515533-15-00 Locally advanced cervical cancer 4